Skip to main content
. 2019 Mar 22;14:683–692. doi: 10.2147/COPD.S194367

Table 2.

Comorbidities within the observation period (including the index date)

Population of interest (N=34,268) Not receiving MITT
Receiving MITT
EOS <150 cells/µL (N=6,892) EOS ≥150 cells/µL (N=16,480) EOS <150 cells/µL (N=3,199) EOS ≥150 cells/µL (N=7,697)

Quan-Charlson Comorbidity 4.4 (3.4) 4.52 (3.43) 4.99 (3.64) 4.83 (3.58) 5.32 (3.69)
Index, mean (SD)
Comorbidities, %
 Hypertension 80.7 77.7 81.6 78.1 82.7
 Diabetes 39.4 34.7 41.3 34.3 41.5
 CHF 44.0 39.5 43.0 45.9 49.2
 AMI 6.9 5.6 6.8 6.9 8.3
 TIA 3.7 3.3 3.8 3.3 3.8
 Stroke 12.5 11.0 12.9 11.3 13.7
 Asthma 34.0 29.5 33.5 35.3 38.4
 Anxiety 37.9 35.6 36.2 41.7 42.2
 Depression 29.2 27.0 29.2 29.6 31.0
 Respiratory infections 24.3 23.6 25.0 22.3 24.3
 Allergic rhinitis 13.8 13.5 14.5 12.7 13.0
 Respiratory tract neoplasm 9.9 9.8 8.4 12.6 12.0
 Acute sinusitis 9.8 10.7 10.5 7.4 8.4
 Chronic sinusitis 7.2 7.2 7.8 6.4 6.2
 GERD 45.7 42.7 46.0 44.0 48.3
 Rheumatoid arthritis 5.7 5.7 5.6 6.2 5.5

Abbreviations: AMI, acute myocardial infarction; CHF, congestive heart failure; EOS, blood eosinophil count; GERD, gastroesophageal reflux disease; MITT, multiple inhaled triple therapy; SD, standard deviation; TIA, transient ischemic attack.